-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Ultragenyx Pharmaceutical, Raises Price Target to $50

Benzinga·08/28/2026 16:48:51
Listen to the news
Wells Fargo analyst Michael Turrin maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and raises the price target from $46 to $50.